Human FGFR3 Protein Active

<strong>Human FGFR3 Protein Active</strong>_x000D_ <strong>Catalog number:</strong> B2014221_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 36.8 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> ‚àí20¬∞C_x000D_ <strong>Keywords:</strong> FGFR3 Protein, active_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, J_nne PA, Aguirre AJ. Acquired Resistance to KRAS(G12C) Inhibition in Cancer N Engl J Med. 2021 Jun 24;384(25):2382-2393._x000D_ 2: Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance Br J Cancer. 2021 Mar;124(5):880-892._x000D_ 3: Duperret EK, Oh SJ, McNeal A, Prouty SM, Ridky TW. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors Cell Cycle. 2014;13(10):1551-9._x000D_ 4: Matsushita M, Kitoh H, Mishima K, Kadono I, Sugiura H, Hasegawa S, Nishida Y, Ishiguro N. Low bone mineral density in achondroplasia and hypochondroplasia Pediatr Int. 2016 Aug;58(8):705-8._x000D_ 5: Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer JCO Precis Oncol. 2022 Nov;6:e2200390._x000D_ 6: Iwata T, Li CL, Deng CX, Francomano CA. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice Hum Mol Genet. 2001 Jun 1;10(12):1255-64._x000D_ 7: Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer Cancer Biol Ther. 2010 Sep 1;10(5):495-504._x000D_ 8: Kamath AV, Lu D, Gupta P, Jin D, Xin Y, Brady A, Stephan JP, Li H, Tien J, Qing J, Damico-Beyer LA. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma Cancer Chemother Pharmacol. 2012 Apr;69(4):1071-8._x000D_ 9: Alatzoglou KS, Hindmarsh PC, Brain C, Torpiano J, Dattani MT. Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations J Clin Endocrinol Metab. 2009 Oct;94(10):3959-63._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/10890204">10: Kuno T, Fujita I, Miyazaki S, Katsumata N. Markers for bone metabolism in a long-lived case of thanatophoric dysplasia Endocr J. 2000 Mar;47 Suppl:S141-4. </a>_x000D_ _x000D_ <strong>Products Related to Human FGFR3 Protein Active can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>